These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1394828)

  • 1. Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group.
    van der Meijden AP; Kurth KH; Oosterlinck W; Debruyne FM
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S95-8. PubMed ID: 1394828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy with early intravesical instillation of adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. The Kyushu University Urological Oncology Group.
    Ueda T; Naito S; Iguchi A; Sagiyama K; Osada Y; Ariyoshi A; Omoto T; Kumazawa J
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S31-6. PubMed ID: 1394813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin.
    Shuin T; Kubota Y; Noguchi S; Hosaka M; Miura T; Kondo I; Fukushima S; Ishizuka E; Furuhata A; Moriyama M
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S52-6. PubMed ID: 7994787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
    Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
    J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.
    Ryoji O; Toma H; Nakazawa H; Goya N; Okumura T; Sonoda T; Kihara T; Tanabe K; Onizuka S; Tomoe H
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S60-4. PubMed ID: 7994789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
    Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
    Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
    Kurth K; Tunn U; Ay R; Schröder FH; Pavone-Macaluso M; Debruyne F; ten Kate F; de Pauw M; Sylvester R
    J Urol; 1997 Aug; 158(2):378-84. PubMed ID: 9224307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. The Hokkaido University Bladder Cancer Collaborative Group.
    Shinohara N; Nonomura K; Tanaka M; Nagamori S; Takakura F; Seki T; Koyanagi T; Togashi M; Maru A
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S41-5. PubMed ID: 7994785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group.
    Eto H; Oka Y; Ueno K; Nakamura I; Yoshimura K; Arakawa S; Kamidono S; Obe S; Ogawa T; Hamami G
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S46-51. PubMed ID: 7994786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M; McGarry R; Kupelnick B
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].
    Flamm J; Kühnel W; Dona S
    Urologe A; 1989 Mar; 28(2):99-102. PubMed ID: 2655259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of intravesical chemoprophylaxis of epirubicin after transurethral resection of bladder tumors. Tottori University Oncology Group.
    Watanabe N; Miyagawa I; Higasibori Y; Nakahara T; Sumi F; Ishida G; Abe B; Inoue A; Hanamoto N
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S57-9. PubMed ID: 7994788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group.
    Okamura K; Murase T; Obata K; Ohshima S; Ono Y; Sakata T; Hasegawa Y; Shimoji T; Miyake K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S31-5. PubMed ID: 7994783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin].
    Hinotsu S; Akaza H; Isaka S; Kagawa S; Koiso K; Kotake T; Machida T; Matsumura Y; Niijima T; Obata K; Ohashi Y; Ohe H; Shimazaki J; Tashiro K;
    Gan To Kagaku Ryoho; 2002 Jan; 29(1):73-80. PubMed ID: 11816482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical instillation of epirubicin: effect on tumour recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour.
    Igawa M; Urakami S; Shirakawa H; Shiina H; Ishibe T; Kadena H; Usui T; Kawanishi M
    Br J Urol; 1996 Mar; 77(3):358-62. PubMed ID: 8814838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
    Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
    J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.
    da Silva FC; Ferrito F; Brandão T; Santos A
    Eur Urol; 1992; 21(1):42-4. PubMed ID: 1606981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III.
    Rajala P; Liukkonen T; Raitanen M; Rintala E; Kaasinen E; Helle M; Lukkarinen O
    J Urol; 1999 Apr; 161(4):1133-5; discussion 1135-6. PubMed ID: 10081854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin.
    Pavone-Macaluso M; Tripi M; Ingargiola GB; Corselli G; Pavone C; Serretta V
    J Chemother; 1993 Jun; 5(3):207-11. PubMed ID: 8371131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy.
    Duque JL; Loughlin KR
    Urol Clin North Am; 2000 Feb; 27(1):125-35, x. PubMed ID: 10696251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.